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Giulio Rastelli*[a]
The design of multi-target ligands has become an innovative
approach for the identification of effective therapeutic treat-
ments against complex diseases, such as cancer. Recent studies
have demonstrated that the combined inhibition of Hsp90 and
B-Raf provides synergistic effects against several types of
cancers. Moreover, it has been reported that PDHK1, which
presents an ATP-binding pocket similar to that of Hsp90, plays
an important role in tumor initiation, maintenance and
progression, participating also to the senescence process
induced by B-Raf oncogenic proteins. Based on these premises,
the simultaneous inhibition of these targets may provide
several benefits for the treatment of cancer. In this work, we set
up a design strategy including the assembly and integration of
molecular fragments known to be important for binding to the
Hsp90, PDHK1 and B-Raf targets, aided by molecular docking
for the selection of a set of compounds potentially able to exert
Hsp90-B-Raf-PDHK1 multi-target activities. The designed com-
pounds were synthesized and experimentally validated in vitro.
According to the in vitro assays, compounds 4a, 4d and 4e
potently inhibited Hsp90 and moderately inhibited the PDHK1
kinase. Finally, molecular dynamics simulations were performed
to provide further insights into the structural basis of their
multi-target activity.
1. Introduction
Multi-target inhibitors, that is small molecules able to simulta-
neously hit multiple targets, have become a major opportunity
in drug discovery.[1–4] Among their several advantages, they
offer the potential of higher efficacy due to synergistic effects, a
minor insurgence of drug resistance, the lack of drug-drug
interactions and a better patient compliance.[1] Indeed, multi-
target drugs are recognized to be particularly important for the
treatment of complex and multi-factorial diseases, such as
cancer and neurodegeneration,[5–8] in which complex networks
of multiple and interconnected biological targets need to be
simultaneously modulated. For this reason, the rational design
of compounds with desired, ad hoc “polypharmacological”
profiles has become increasingly important to discover better
drug candidates.[9]
Being responsible for the assembly and regulation of a large
number of signal transduction and regulatory client proteins,
the molecular chaperone Heat shock protein 90 (Hsp90) is a key
node in many biological processes,[10] hence it represents an
excellent candidate for drug polypharmacology.[11–14] Hsp90
refolds, stabilizes and regulates the trafficking of many proteins
involved in uncontrolled proliferation and apoptotic resistance,
including, but not limited to, multiple protein kinases of the so-
called Hsp90 interactome. Importantly, Hsp90 regulates a
number of cellular and disease-related processes, many of
which involve mutant and overexpressed oncoproteins whose
activity and regulation depend on Hsp90 activity.[15] Of note,
while recent studies showed that administration of a single
Hsp90 inhibitor suffers from non-optimal safety profiles or lack
of efficacy,[16] promising drug combinations based on Hsp90
and B-Raf inhibitors are currently under clinical evaluation
against mutated melanoma with promising results (clinical-
trials.gov ID: NCT02721459, NCT01657591). Hsp90 inhibition
contributes to the degradation of wild type and V600E mutant
B-Raf kinases.[17] Moreover, such combinations have demon-
strated to provide significant synergistic effects against several
types of cancers,[18–22] and inhibition of Hsp90 proved to be
effective in patients with intrinsic or acquired resistance to Raf
inhibitors.[15–21] In the context of tumorigenesis, another relevant
target is Pyruvate dehydrogenase kinase 1 (PDHK1), an enzyme
that inhibits the pyruvate dehydrogenase complex preventing
conversion of pyruvate to acetyl-CoA, the substrate for the
Krebs’ cycle.[23] Activation of PDHK1 results in the uncoupling of
glycolysis to glucose oxidation. Moreover, PDHK1 is overex-
pressed in melanoma patients, this effect being associated with
the expression of the mTOR pathway effectors and independent
of the B-Raf mutational status.[24] Notably, PDHK1 is not only
required for tumor initiation, but also for tumor maintenance
and progression, suggesting that targeting PDHK1 may be
beneficial for therapeutic intervention in melanoma.[25] In
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particular, PDHK1 plays an important role in oncogene-induced
senescence in B-RafV600E melanoma,[25] and the kinase itself is an
Hsp90 client adopting a similar fold to that of Hsp90.[26]
In the light of all these considerations, we reasoned that an
Hsp90 inhibitor with B-Raf and PDHK1 kinases multi-target
activity could be of particular interest for cancer treatment. In
this study, we describe the design, synthesis and biological
evaluation of a small set of potential multi-target ligands
assembled by integrating Hsp90, B-Raf and PDHK1 key molec-
ular fragments. In particular, the design included an analysis of
available crystal structures of ligands in complex with the three
targets, as well as docking simulations into selected conforma-
tions of the B-Raf, PDHK1 and Hsp90 binding sites. Although
potent inhibitors of Hsp90 were obtained, the resulting
compounds did not inhibit B-RafWT and B-RafV600E. However, they
showed moderate inhibitory activity against PDHK1. The bind-
ing mode of the more interesting compounds was further
investigated by means of molecular dynamics simulations, in
order to shed light into the observed activity profile.
2. Results and Discussion
2.1 Molecular Design
The multi-target compounds were designed by assembling and
integrating scaffolds known to be important for binding to
Hsp90, PDHK1 and B-Raf (Figure 1).
In particular, an analysis of potent Hsp90, PDHK1 and B-Raf
inhibitors reported in the literature was performed, allowing the
selection of the resorcinol-substituted 1,2,3-triazole Hsp90
ligands reported by Taddei et al.,[27] the 4,5-diarylisoxazole
PDHK1 modulators designed by Meng et al.[28] and the pyrazole-
pyridine B-Raf compounds developed by Hansen et al.,[29] as
suitable initial structural templates for the design of multi-target
ligands (Figure 1, panel a). The selected resorcinol-substituted
1,2,3-triazole Hsp90 inhibitors share significant structural sim-
ilarity with the 4,5-diarylisoxazole PDHK1 ligands, the highest
similarities evaluated between molecules of these targets being
almost 1.0 in terms Tanimoto coefficient for both MACCS and
ECFP4 molecular fingerprints (see the “Chemoinformatic analy-
ses” section in the Supporting Information). Slightly different
considerations could be drawn for the selected B-Raf com-
pounds, which share with the diaryl-triazole Hsp90 ligands and
the diaryl-isoxazole PDHK1 molecules a system composed by
three differently substituted aromatic rings, resulting in signifi-
cant similarity in terms of structural connectivity (see the
Supporting Information). Visual inspection of reported Hsp90,
PDHK1 and B-Raf crystal structures highlighted different struc-
tural requirements at the three aromatic rings of the selected
ligands. Therefore, the phenyl-triazole and phenyl-isoxazole
chemical fragments were selected as starting points for the
design of the desired multi-target ligands. Notably, replacing
the phenyl ring of selected phenyl-triazole Hsp90 and phenyl-
isoxazole PDHK1 inhibitors with a pyridine ring allowed us to
introduce the nitrogen atom required for the binding to the
backbone of the Cys532 hinge residue in B-Raf, as evidenced
from the crystallographic structure reported by Hansen et al.
(PDB code 3D4Q).[29] Moreover, the performed analyses allowed
also to identify significant similarity between some of the more
sterically hindered amide substituents of the selected Hsp90
and PHDK1 inhibitors with the phenyl-3-sulfonamide and
phenyl-3-sulfamide chemical moieties of B-Raf ligands reported
Figure 1. Design of Hsp90 inhibitors 4a–4f with putative multi-target
activity. The compounds were obtained by firstly assembling selected
molecular core scaffolds of known Hsp90 inhibitors (i. e., substituted
resorcinol, 4-phenyl-1,2,3-triazole molecules),[19] with those selected from
reported PDHK1 ligands (based on substituted resorcinol, 4-phenyl-(1,2-
oxazole)),[28] and B-Raf ligands (based on substituted 4-(1H-pyrazol-3-yl)
pyridine) (panel a).[29–31] Further similarity estimations performed on selected
inhibitors of these proteins allowed to identify chemical substituents
conferring high potency and selectivity towards B-Raf protein kinases,[30,31]
which are expected to be well accepted also by Hsp90 and PDHK1. Panel b
reports few among the most similar Hsp90 and PDHK1 amide substituents,
identified with respect to unsubstituted (R1, R2=H) and substituted (R1,
R2=F) phenyl-3-sulfonamides or phenyl-3-sulfamides chemical moieties
present in the selected B-Raf compounds. The assembled molecular core
scaffold and selected substituents were finally integrated into chemical
entities with the structural details potentially required to achieve efficient
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by Mathieu et al.[30] and Wenglowsky et al.[31] (Figure 1, panel b),
which are engaged in hydrogen bonds to the DFG motif and
occupy a small lipophilic pocket of the kinase (see the
Supporting Information).
The performed analyses allowed us to design an initial
structural core, integrating different structural details of the
selected Hsp90, PDHK1 and B-Raf ligands (Figure 1, panel c),
and thus proposing six derivates (4a–4f) potentially able to
interact with the hot spot residues of the selected targets, as
indicated by the corresponding crystal structure complexes. The
chemical structures of the 4a–4f designed compounds are
shown in Figure S1 in the Supporting Information. The
computationally designed ligands were then docked into
representative crystal structures of the three targets, to evaluate
whether they are able to provide favorable docking scores and
a binding mode consistent with the reported crystal structure
information.
2.2 Molecular Docking
Compounds 4a–4f were docked into the 2VCI crystal structure
of Hsp90 (see experimental methods for details),[32] showing a
binding mode fully consistent with that of the 2GJ crystallo-
graphic ligand. In particular, the hydroxyl groups of the
resorcinol moiety hydrogen bonded to Asp93 and three buried,
highly conserved water molecules, the amide nitrogen estab-
lished an H-bond interaction with the backbone carbonyl of
Gly97, while the pyridine and the aryl sulfonamides or
sulfamides were directed outwards. Interestingly, pKa predic-
tions made with Epik (Schrödinger Suite 2020–1)[33,34] showed
that the 2,6-difluoro substituted sulfonamides 4b–4d and
sulfamides 4e–4f were ~1 and ~1.5 pKa units more acidic with
respect to the unsubstituted compound 4a (Table S1 in the
Supporting Information), suggesting that the former derivatives
could bind the protein in their anionic form. This observation is
consistent with the electronic effect of an ortho/para di-fluoro
substitution on the acidity of an aryl sulfonamide. Therefore,
4b–4f were modelled in their anionic form. Of note, a
deprotonated form would potentially favor an interaction with
mutant B-RafV600E, as previously discussed by Tsai et al.[35]
Docking scores are reported in Table S2 in the Supporting
Information.
Docking calculations predicted that 4a–4f are accommo-
dated into the ATP binding site of B-Raf (PDB code: 3D4Q),[29]
with the pyridine nitrogen hydrogen bonded to the Cys532
residue of the hinge, in agreement with the location of the
pyridine of ligand SM5 in the experimental complex.[29] The aryl
sulfonamide and sulfamide moieties of the ligands interacted
with the DFG motif of the kinase, with the small lipophilic tails
filling a narrow pocket formed by an outward shift of the αC-
helix, similarly to experimentally observed complexes of RI8
(PDB code: 4EHG), RI9 (PDB code: 4EHE), and BR2 PDB code:
3SKC) crystallographic compounds reported by Mathieu et al.[30]
and Wenglowsky et al.[31] Docking scores of the compounds into
B-Raf are reported in Table S2 in the Supporting Information.
Finally, docking of 4a–4f into the ATP site of PDHK1 (PDB
code: 2Q8G)[26] provided binding modes fully comparable to
those obtained in Hsp90. Interestingly, the observed binding
poses are consistent, to some extent, with the fact that PDHK1
and Hsp90 have similar folds and share a certain degree of
residue conservation of their ATP sites, and that the binding
mode of the resorcinol inhibitor radicicol is very similar in the
two proteins.[26,36] The docking scores observed for 4a–4f in the
PDHK1 binding site are reported in Table S2 in the Supporting
Information.
2.3 Synthesis of Compounds 4a–4f
In line with our previous experience on triazole
compounds,[37–39] the synthetic construction of inhibitors 4a–4f
was accomplished by a multistep procedure. The preparation of
triazole 1 (Scheme 1) is based on Huisgen cycloaddition
between azide C and ethyl 3-(pyridin-4-yl)-propiolate and
subsequent base induced ester hydrolysis.
Azide C was prepared according to a six-step procedure.[27]
Dibenzyl 4-acetylresorcinol was used as starting material and
the acetyl group was converted into the i-propyl group by
Wittig reaction and hydrogenation. Benzylation reaction was
necessary to reintroduce the benzyl groups. The azide group
was then introduced by conventional procedure, that is the
nitration of compound B, followed by reduction and subse-
quent diazotization-azidation reaction. Triazole D was isolated
in high yield as a single regioisomer by 1,3-cycloaddition
reaction catalyzed by (Cp*RuCl)4 under classical reaction
conditions as reported by Weinreb et al.[40]
Compound 2a is commercially available. Compounds 2b–f
were synthetized following literature protocols.[41] Condensation
of the common scaffold 1 with various substituted anilines 2a–f
in the presence of HATU as condensing agent (see experimental
methods for details) afforded the desired protected compounds
3a–f with satisfactory yields (Table 1). It is worth of note that
the presence of fluorine atoms on the aniline aromatic ring
(R2 =F, 2b–f) resulted in a lower reactivity of 2b–f in the
condensation reaction. The final cleavage of the benzyl
protecting groups in the presence of BBr3 afforded compounds
4a–f in good yield after purification (Table 2).
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2.4 Enzyme Inhibitory Activities
Compounds 4a–4e were tested in vitro to evaluate their
inhibitory activity on Hsp90, B-Rafwt, B-RafV600E and PDHK1
recombinant, purified enzymes (see experimental section for
details). The IC50 values of compounds 4a–4f along with the
IC50 values of the control inhibitors used in the enzymatic assay
are reported in Table 3, while dose-response curves of the
active compounds are reported in Figure S2 in the Supporting
Information. Compounds 4a, 4d and 4e turned out to be
potent nanomolar inhibitors of Hsp90, their IC50 values being
7 nm, 30 nm and 8 nm. The remaining derivatives, that is 4b, 4c
and 4f were active in the low micromolar range. All compounds
were also tested for the inhibition of the PDHK1 and B-Raf
proteins. None of the tested compounds were active against B-
RafWT or B-RafV600E. However, 4a, 4d and 4e inhibited PDHK1
with IC50 values of 28.7, 38.7 and 29.4 μm, the compounds
being only four-fold less active than the control inhibitor
GW5074 (Table 3).
In silico predictions made with the CLC-pred webserver
(http://www.way2drug.com/cell-line/, accessed on August 27th,
2021)[42] suggest that the designed compounds could show
cytotoxic effects against, for example, non-small cell lung
cancer (NSCLC) and melanoma cancer cells, while not providing
significant cytotoxicity on normal human cell lines (see Table S3
in the Supporting Information). These results are particularly
interesting, considering that Hsp90 and the other investigated
targets have been previously studied for NSCLC treatment.[43–45]
2.5 Molecular Dynamics
Molecular dynamics simulations were performed to provide
further insights into the observed inhibitory activity profiles.
Considering that in Hsp90 the di-fluoro substituted compound
4b was ~250-fold less active than 4a, but 4e retained high
potency despite bearing a di-fluoro substitution, compounds
4a, 4b and 4e were considered interesting enough to be
selected for further investigation with molecular dynamics
(MD). After equilibration, the average root mean square
deviations (RMSD) of ligands and binding site residues, along
the 100 ns MD production run of each Hsp90-ligand complex
were fairly low. Figure S3 in the Supporting Information shows
schematic representations of the hydrogen bond interactions
sampled by MD (left panels), along with representative
minimized structures (right panels) of each Hsp90-ligand
complex. Table S4 in the Supporting Information reports the
percentages of occurrence of hydrogen bond interactions along
the simulated MD trajectory (100 ns) and the resulting average
hydrogen bond distances in Å. Interestingly, the percentage of
occurrence of hydrogen bond interactions between the amide
nitrogen of 4b and the backbone carbonyl of Gly97 was
significantly lower compared to that of 4a (36% vs 80%,
Table S4 in the Supporting Information). Moreover, the average
torsion angle of the 2,6-diflurophenyl ring of 4b relative to the
amide moiety was nearly orthogonal (80°), while the corre-
sponding angle of the unsubstituted compound 4a was only
52° out of plane. These results suggest that the 2,6-difluoro
substituent reduced the ability of the amide moiety to hydro-
gen bond to Gly97, owing to steric effects. In addition,
compound 4a with a neutral sulfonamide hydrogen bonded to
Asp102 with 94% occurrence (Table S4 in the Supporting
Information), while such interaction was not observed in the
ionized sulfonamide 4b, which hydrogen bonded to Lys58 and
His154 with only 17% and 7% occurrences, respectively.
Altogether, these findings may explain the lower activity of 4b
Table 1. Synthesis of compounds 3a–f.
Compound R1 R2 Yield [%]
3a   CH3 H 85
3b   CH3 F 47
3c   CH2  CH3 F 61
3d   (CH2)2  CH3 F 49
3e   N(CH2)4 F 54
3f   N(CH3)2 F 57
Table 2. Deprotection of 3a-f to give compounds 4a–f.
Compound R1 R2 Yield [%]
4a   CH3 H 78
4b   CH3 F 89
4c   CH2  CH3 F 95
4d   (CH2)2  CH3 F 98
4e   N(CH2)4 F 84
4f   N(CH3)2 F 85
Table 3. Inhibitory activities (IC50, μm) of compounds 4a–4f against
Hsp90α, B-RafWT, B-RafV600E and PDHK1. Dose-response curves of the active









controls 0.009[a] 0.044[b] 0.006[b] 7.1[b]
4a 0.007 inactive inactive 28.7
4b 1.7 inactive inactive inactive
4c 1.1 inactive inactive inactive
4d 0.03 inactive inactive 38.3
4e 0.008 inactive inactive 29.4
4f 0.5 inactive inactive inactive
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with respect to 4a. Compound 4e with a pyrrolidine sulfamate
resulted in a hydrogen bond network similar to that of 4b
(Table S4 in the Supporting Information), but the additional
pyrrolidine ring fitted snugly into a hydrophobic crevice lined
by Ile96 (Figure S3 in the Supporting Information), thus explain-
ing the recovered activity of 4e compared to 4b.
Although 4a–4f docked well into B-Raf, showing favorable
docking scores and binding modes consistent with those
experimentally observed in the 3D4Q[29] and 4EHG[30] crystallo-
graphic complexes, none of the designed ligands resulted to be
active in vitro (Table 2). To shed light into this discrepancy, a
MD simulation of the B-Raf complex with 4e, which is the
compound with the best docking score (Table S2 in the
Supporting Information), was performed.
As described in the “molecular docking” section (see above),
the pyridine nitrogen atom of 4e established a H-bond
interaction with the backbone of the Cys532 hinge amino acid,
the hydroxyl group hydrogen bonded with His539, and the
sulfonamide group hydrogen bonded with the Asp594, Phe595
(of the DFG) and Lys483 (the conserved lysine) residues of the
kinase (Figure S4 in the Supporting Information, panels a and
b). However, after 20 ns of MD simulation, the pyridine ring
moved far away from the hinge and the ligand lost most of the
interactions with B-Raf (Figure S4 in the Supporting Information,
panel c). These results were rather unexpected, and contra-
dictory compared to the docking results. We hypothesized that
the compound was not able to efficiently accommodate within
the B-Raf binding site due to steric hindrance, which prevented
it to stably place the pyridine ring in the hinge and the
sulfonamide in the DFG pocket. Future work should consider
shorter and less constrained molecules. Altogether, these results
show how delicate is the design of multi-target ligands that
bind to targets with different architecture, especially when
more than two targets are taken into consideration, as done in
the present work. Indeed, the results of this study showed how
the integration of different in silico approaches, e. g. docking
and molecular dynamics, would provide more robust results in
the validation of suitable candidates with respect to the
application of a single approach.[46]
Finally, complexes of PDHK1 with compounds 4a and 4e
were also further investigated by means of MD. As expected,
the interactions established by the resorcinol moiety of 4a and
4e were very similar to those observed in Hsp90 (Figure S5 and
Table S5 in the Supporting Information), the Asp318 residue in
PDHK1 corresponding to Asp93 in Hsp90. However, the amide
moiety of the two inhibitors gave marginal hydrogen bonds
with the backbone carbonyl of Gly322, this residue correspond-
ing to Gly97 in Hsp90. Rather, the amide moiety hydrogen
bonded with Gly320, but again with very low percentages of
occurrence (Table S5 in the Supporting Information). These
findings may explain the lower inhibitory activity of 4a and 4e
towards PDHK1 compared to Hsp90. Moreover, the hydro-
phobic crevice formed by Ile96 in Hsp90 is not present in
PDHK1, this residue being a glycine in the latter protein, further
explaining the lower activity of this compound.
Conclusion
In this study, we have designed and synthesized a set of novel
potential multi-target ligands by integrating molecular frag-
ments selected from known Hsp90, B-Raf and PDHK1 inhibitors.
The study led to the identification of three potent inhibitors of
Hsp90 with moderate PDHK1 inhibitory activity. Although
activity against B-Raf could not be obtained, the results herein
presented are of significance, considering that three different
biological targets were simultaneously addressed. The com-
pounds were designed by following an integrated scaffold
approach and exploiting crystal structure information, with the
goal of keeping the molecular weight of the resulting
compounds to a minimum. Before their synthesis, the designed
compounds were validated by means of docking simulations
into selected B-Raf, Hsp90 and PHDHK1 conformations. The
binding modes of the newly discovered dual Hsp90/PDHK1
inhibitors were investigated by means of molecular dynamics
simulations, providing interesting explanations to the observed
activity profiles. The rational design of multi-target ligands has
become a valuable opportunity and a real challenge in
medicinal chemistry.[1–4,47,48] The data reported in this study is
expected to pave the way to further rational design and




The designed ligands were prepared for the structure-based
calculations by using the LigPrep (Schrödinger 2020–1) utility,[49]
available in Maestro (Schrödinger 2020–1).[50] pKa predictions were
performed using Epik.[33] Structure-based calculations were per-
formed into the 2VCI,[32] 2Q8G[26] and 3D4Q[29] crystal complexes of
Hsp90, PDHK1 and B-Raf, respectively. In particular, crystal
structures were firstly pre-processed with the Protein Preparation
Wizard utility.[51] Atom types and bond connectivity issues were
fixed, hydrogen atoms added and H-bond networks optimized.
Ions, water and solvent molecules were also removed from the
complexes, except for the three buried water molecules that
establish a conserved H-bond networks with the ligands in Hsp90
and PDHK1.[26,32,52] Then, docking of ligands into the binding sites of
the investigated targets was performed by using the multistage
Induced Fit docking (IFD) protocol available in Maestro of
Schrödinger suite 2020–1.[53,54] Re-docking of the crystallographic
compounds into their parent complexes was performed, providing
satisfactory results (RMSD<2.0 Å). IFD calculations were performed
with default settings, by focusing the calculations at the centroids
of the co-crystallized ligands for Hsp90 and B-Raf. None of the
PDHK1 crystal structures available in the PDB contained a ligand
bound in the ATP site. Therefore, in this case the center of the
ligand box was determined by superimposing the crystal structure
of PDHK1 (PDB code: 2Q8G) with that of the homologous PDHK3
enzyme in complex with radicicol (PDB code: 2Q8I),[26] which shows
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Molecular Dynamics
The molecular mechanics (MM) parameters for ligands 4a, 4b and
4e (atom types and atomic charges) were assigned with the
Antechamber module of Amber 18.[55] In particular, the ligands
were assigned generalized amber force field (GAFF2)[56] atom types
and AM1-BCC[57] atomic charges. Missing force-field parameters
were assigned with the PARMCHECK utility.[55] Starting from the
docking complexes, hydrogen atoms were added to the complexes
using the internal coordinates of the Amber all-atom data base. All
Lys and Arg residues were positively charged and Glu and Asp
residues negatively charged. All calculations in this study were
performed with the Amber 18[55] suite of programs, and the ff14SB
force field[58] for the protein and the GAFF2[56] force field for the
ligands. Each protein-ligand complex was solvated in an octahedral
box of TIP3P[59] water molecules centered on the ligand and
extending 10 Å outside the protein on all sides. The CUDA version
of PMEMD was used to perform all molecular mechanics and
molecular dynamics calculations.[55] The simulations employed a
residue-based cut-off of 10 Å, a time step of 2 fs, and a constraint of
bond lengths involving hydrogen atoms using the SHAKE[60]
algorithm. The solvated complexes were minimized with 10000
steps of conjugate gradient minimization and equilibrated with MD
at 300 K as follows. First, 100 ps MD at constant volume (NVP) with
2 kcalmol  1 Å  2 restraint on the protein and the ligand were
performed in order to gradually heat the system from 0 K to 300 K
without undesirable drifts of the structures. Then, MD was
continued under constant pressure conditions (NPT, 1 atm) for
100 ps with 1 kcalmol  1Å  2 restraint on the same atoms, followed
by additional 100+100 ps MD with gradually reduced restraints
(0.5 and 0.2 kcalmol  1Å  2). Afterwards, the complexes were equili-
brated for 40 ns, without restraints. After equilibration, production
runs the length of 100 ns each were performed, and coordinates
were collected every 10 ps, resulting in a ten thousand snapshots
collected for each trajectory. The coordinates were also averaged
every 2 ns for visual inspection. Hydrogen bond and root mean
squared deviation analyses on the trajectories were made with the
CPPTRAJ module of Amber 18.[55]
Chemical Synthesis
General Procedures
All available chemicals and solvents were purchased from commer-
cial sources and were used without any further purification. Thin
layer chromatography (TLC) was performed using 0.25 mm silica
gel precoated plates Si 60-F254 (Merck, Darmstadt, Germany)
visualized by UV-254 light and CAM staining. Purification by flash
column chromatography (FCC) was conducted by using silica gel Si
60, 230–400 mesh, 0.040–0.063 mm (Merck). Melting points were
determined on a Stuart Scientific SMP3 and are corrected. 1H and
13C NMR spectra were recorded on a Bruker Avance 400 (400 and
101 MHz, respectively) or Bruker Fourier 300 (300 and 75 MHz,
respectively); chemical shifts are indicated in parts per million
downfield from SiMe4, using the residual proton (CHCl3 =7.26 ppm;
DMSO=2.54 ppm) and carbon (CDCl3 =77.0; ppm; DMSO=
40.0 ppm) solvent resonances as internal reference. Protons and
carbon assignments were achieved by 13C-APT, 1H-1H COSY, and
1H-13C heteronuclear correlation experiments. Coupling constants
values J are given in Hz.
Synthesis and Characterization of New Compounds
Ethyl 1-[2,4-bis(benzyloxy)-5-isopropylphenyl]-5-(pyridin-4-yl)-
1H-1,2,3-triazole-4-carboxylate (D)
[Cp*RuCl]4 (540 mg, 0.48 mmol) was added to a stirred solution of
alkyne (ethyl 3-(pyridin-4-yl)propiolate; 1.05 g, 6.0 mmol) and azide
C (2.46 g, 6.6 mmol) in anhydrous DMF (8 ml) under nitrogen
atmosphere at room temperature. After 16 h, water was added and
the reaction was extracted with AcOEt (3×15 mL), washed with
brine (1×5 mL) and dried with MgSO4. The solvent was removed
under reduced pressure and the residue was purified by FCC –
AcOEt/hexane (3 :7) – on silica gel to afford triazole D as a yellow
solid (2.93 g, 89%). 1H NMR (300 MHz, CDCl3) δ 8.46 (d, 2H, J=5.5),
7.68–7.39 (m, 11H), 6.94 (d, 2H, J=5.30), 6.46 (s, 1H), 5.07 (s, 2H),
4.61 (s, 2H), 4.44–4.42 (m, 2H), 3.36–3.30 (m, 1H), 1.38 (t, 3H, J=7.3)
1.34(s, 3H), 1.22 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 161.5, 158.9,
151.8, 149.7 (2CHAr), 140.6, 137.12, 136.9, 135.8 (2CAr), 129.3, 129.0–
128.1 (10CHAr), 125.0 (2CHAr), 124.1, 117.6, 99.4, 72.0, 71.5, 62.9, 27.1,




LiOH (359 mg, 15.0 mmol) was added to a solution of compound D
(2.74 g, 5.0 mmol) in a 1 :1 mixture of THF:H2O (50.0 mL). The
reaction mixture was stirred at room temperature until completion
(4 h), then was concentrated and quenched with HCl 1 N (5 mL).
After extraction with AcOEt (2×20 mL), the collected organic
phases were washed with water (1×10 mL), brine (1×10 mL) and
dried over Na2SO4. Evaporation of the solvent in vacuum afforded
compound 1 as a brown solid (2.47 g, 95%). 1H NMR (300 MHz,
CDCl3) δ 13.19 (bs, 1H), 8.54 (d, 2H, J=5.2 Hz), 7.42–7.33 (m, 9H),
7.23 (d, 2H, J=6.0), 7.14 (s, 1H), 7.21 (s, 1H), 6.90 (s, 1H), 5.13 (s, 2H),
5.01 (s, 2H), 3.21–3.14 (m, 1H), 1.12 (s, 3H), 1.09 (s, 3H); 13C NMR
(75 MHz, CDCl3) δ 166.1, 156.3, 152.1, 149.8 (2CHAr), 140.4, 136.5,
134.9 (2CAr), 129.4, 129.0, 128.4–127.7 (10CHAr), 126.4 (2CHAr), 124.4,
117.7, 99.1, 70.4 (2CH2), 26.7, 23.2 (2CH3). Anal. Calcd. For
C31H28N4O4. C, 71.52; H, 5.42; N, 10.76. Found: C, 71.41; H, 5.33; N,
10.88.
General Procedure for the Preparation of Products 3a–f.
To a stirred solution of carboxylic acid 1 (520 mg, 1.00 mmol) in
15 mL of anhydrous DCM and 0.5 mL of DIPEA were added
compound 2a–f (1.20 mmol) and HATU (570 mg, 1.5 mmol) at
room temperature under nitrogen atmosphere. The reaction
mixture was magnetically stirred at room temperature for 4 h, then
was quenched by HCl 1 M and extracted with DCM (2×10 mL). The
collected organic phases were washed with brine (1×10 mL), dried
over Na2SO4 and the solvent was evaporated under vacuum (RV).
The resulting crude was purified by FCC – AcOEt/hexane (1 :1) – on
silica gel. Yield, physical, spectroscopic and analytical data of




2a (223 mg). 3a (585 mg, 85%). 1H NMR (300 MHz, DMSO-d6) δ 9.33
(bs, 1H), 8.65–8.64 (m, 2H), 8.29 (s, 1H), 7.95 (s, 1H), 7.38–7.16 (m, 14
H), 6.92–6.89 (m, 2H), 6.58 (s, 1H), 4.99 (s, 2H), 4.70 (s, 2H), 3.36–3.27
(m, 1H), 3.12 (s, 3H), 1.21(s, 3H), 1.18(s, 3H); 13C NMR (75 MHz,
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138.7, 138.1, 138.0, 131.9, 129.4, 128.2–127.2 (8CAr, 4CHAr), 125.0,
124.6, 122.2, 120.3, 120.0, 115.7, 103.1, 72.9, 72.8, 41.0, 24.5, 21.3 (2
CH3). Anal. Calcd. For C38H36N6O5S: C, 66.26; H, 5.27; N, 12.20. Found:




2b (267 mg). 3b (341 mg, 47%). 1H-NMR (300 MHz, DMSO-d6) δ
9.00 (bs, 1H), 8.45 (d, 2H, J=5.4 Hz), 7.37–7.28 (m, 9H), 7.17–7.15 (d,
2H, J=5.5 Hz), 7.03–7.01 (m, 1H), 6.96–6.95 (m, 2H), 6.75 (t, 1H, J=
9.2 Hz), 6.70 (s, 1H) 6.57 (bs, 1H), 5.13 (s, 2H), 4.84 (s, 2H), 3.52 (s,
3H), 3.24–3.22 (m, 1H), 1.13 (s, 3H), 1.11 (s, 3H); 13C NMR (75 MHz,
DMSO-d6) δ 159.9, 154.2, 153.3–150.0 (m, 2CFAr), 151.5, 151.0, 149.4
(2CAr), 145.9, 138.1, 136.7, 133.1–122.4 (13CAr, 6CHAr), 120.0, 101.7,
73.9, 73.8, 50.3, 25.0, 23.9 (2CH3). Anal. Calcd. For C38H34F2N6O5S: C,




2c (283 mg). 3c (451 mg, 61%). 1H NMR (400 MHz, DMSO-d6) δ 8.86
(bs, 1H), 8.55 (d, 2H, J=5.1 Hz), 7.53 (d, 2H, J=5.1 Hz), 7.40–7.28 (m,
9H), 7.23 (d, 2H, J=5.6 Hz), 7.03–7.01 (m, 1H), 6.96–6.94 (m, 2H),
6.45 (s, 1H), 5.00 (s, 2H), 4.74 (s, 2H), 3.39–3.30 (m, 1H), 3.15–3.08 (m,
2H), 1.40 (t, 3H, J=7.5 Hz), 1.23 (s, 3H), 1.21 (s, 3H); 13C NMR
(100 MHz, DMSO-d6) δ 162.1, 155.0, 152.6–150.1 (m, 2CFAr), 151.3,
150.1, 149.6 (2CAr), 146.0, 138.5, 137.7, 134.1–122.1 (13CAr, 6CHAr),
120.0–119.9 (m, 1CHAr), 102.3, 74.3, 74.2, 51.1, 24.8, 23.9 (2 CH3),
15.9. Anal. Calcd. For C39H36F2N6O5S: C, 63.40; H, 4.91; N, 11.38.




2d (300 mg). 3d (369 mg, 49%). 1H NMR (300 MHz, CDCl3) δ 8.82
(bs, 1H), 8.51 (d, 2H, J=5.5 Hz), 7.50 (d, 2H, J=5.5 Hz), 7.37–7.26 (m,
9H), 7.19 (d, 2H, J=5.6 Hz), 7.00 (t, 1H, J=7.2 Hz), 6.92–6.89 (m, 2H),
6.41 (s, 1H), 4.97 (s, 2H), 4.71 (s, 2H), 3.34–3.27 (m, 1H), 3.06–3.01 (m,
2H), 1.89–1.82 (m, 2H), 1.20 (s, 3H), 1.18 (s, 3H), 1.02 (t, 3H, J=
7.1 Hz); 13C NMR (75 MHz, CDCl3) δ 164.6, 156.6, 153.8–151.1 (m,
2CFAr), 151.0, 149.6, 149.4 (2CAr), 145.8, 138.1, 187.9, 133.3–122.2
(13CAr, 6CHAr), 119.5–119.3 (m, 1CHAr), 101.4, 72.3, 72.2, 52.9, 25.2,
24.4 (2CH3), 18.6, 11.2. Anal. Calcd. For C40H38F2N6O5S: C, 63.82; H,




2e (302 mg). 3e (407 mg, 54%). 1H NMR (300 MHz, CDCl3) δ 8.89
(bs, 1H), 8.45 (d, 2H, J=5.4 Hz), 7.74 (d, 2H, J=5.4 Hz), 7.39–7.35 (m,
6H), 7.29–7.27 (m, 5H), 7.22–7.20 (m, 1H), 7.04–7.01 (m, 2H), 6.71 (s,
1H), 5.12 (s, 2H), 4.86 (s, 2H), 4.01–3.97 (m, 1H), 3.81 (s, 6H), 1.19 (s,
3H), 1.16(s, 3H); 13C NMR (75 MHz, DMSO-d6) δ 161.9, 155.7, 154.4,
152.7–150.0 (m, 2CFAr), 149.5 (2CHAr), 141.4, 137.0, 136.9, 135.9,
135.0, 131.3, 129.6–128.5 (1CAr, 10CHAr), 126.1 (2CHAr), 125.9, 124.3,
118.2, 118.0, 112.4, 103.3, 72.2, 72.1, 46.1 (2CH3), 27.0, 22.4 (2CH3).
Anal. Calcd. For C39H37F2N7O5S: C, 62.14; H, 4.95; N, 13.01. Found: C,




2e (333 mg). 3e (445 mg, 57%). 1H NMR (300 MHz, CDCl3) δ 8.91
(bs, 1H), 8.56–8.54 (d, 2H, J=Hz), 7.59–7.57 (m, 2H), 7.44–7.31 (m,
9H), 7.24 (d, 2H, J=5.5 Hz), 7.04–7.02 (m, 3H), 6.65 (s, 1H), 5.06 (s,
2H), 4.82 (s, 2H), 3.49–3.34 (m, 5H), 1.89–1.85 (m, 4H), 1.25(s, 3H),
1.23 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 160.4, 155.9, 153.0, 152.6–
149.7 (m, 2CFAr), 150.1 (2CHAr), 142.2, 138.5, 135.6, 135.5, 135.1,
130.9, 130.1–128.5 (1CAr, 10CHAr), 126.7 (2CHAr), 126.0, 124.0, 117.8,
116.9, 111.1, 104.1, 73.2, 73.1, 46.9 (2CH2), 27.3, 23.9 (2CH3), 22.5
(2CH2). Anal. Calcd. For C41H39F2N7O5S: C, 63.15; H, 5.04; N, 12.57.
Found: C, 63.43; H, 5.22; N, 12.41.
General Procedure for the Synthesis of Products 4a–f
To a solution of 3a-f (0.3 mmol) in DCM dry (3 mL) was added BBr3
1 M in DCM (0.6 mL, 0.6 mmol) under nitrogen atmosphere at
  78 °C. Then, the mixture was stirred at room temperature over-
night. The reaction was cooled to 0 °C, methanol was added
dropwise and the solvent was removed under vacuo. The residual
was dissolved in ethyl acetate and washed with HCl 1 M (1×5 mL),
brine (1×5 mL), dried over Na2SO4, and the solvent was removed
under vacuo. The crude was purified by FCC – MeOH/DCM (5 :95) –
on silica gel. Yield, physical, spectroscopic and analytical data of
products 4a–f are as follows.
1-(2,4-dihydroxy-5-isopropylphenyl)-N-[3-(methylsulfonamido)
phenyl]-5-(pyridin-4-yl)-1H-1,2,3-triazole-4-carboxamide (4a)
3a (207 mg). 4a (119 mg, 78%). 1H NMR (400 MHz, DMSO-d6) δ 9.01
(bs, 2H), 8.69 (d, 2H, J=5.3 Hz), 7.81 (d, 2H, J=5.3 Hz), 7.89 (s, 1H),
7.61–7.52 (m, 4H), 6.77 (bs, 1H), 6.49 (s, 1H), 5.79 (bs, 1H), 3.17–3.13
(m, 1H), 3.00 (s, 3H), 1.10 (s, 3H), 1.08 (s, 3H); 13C NMR (75 MHz,
DMSO-d6) δ 163.0, 155.8, 152.2, 149.9 (2CHAr), 142.3, 139.1, 138.5,
134.0, 130.9, 129.2, 128.2, 124.9 (2CHAr), 124.0, 120.1, 119.4, 119.3,
114.7, 104.4, 42.1, 26.0, 21.4 (2CH3). Anal. Calcd. For C24H24N6O5S: C,




3b (217 mg). 4b (145 mg, 89%). 1H NMR (400 MHz, DMSO-d6) δ
9.82 (bs, 3H), 8.63–8.61 (m, 2H), 7.31–7.29 (m, 2H), 7.02 (s, 1H), 6.95–
6.93 (m, 1H), 6.72–6.69 (m, 1H), 6.37 (s, 1H), 5.49 (bs, 1H), 3.19 (s,
3H), 3.07–3.01 (m, 1H), 1.06 (s, 3H), 1.04 (s, 3H); 13C NMR (100 MHz,
DMSO-d6) δ 161.7, 154.1, 151.7, 152.1–149.5 (m, 2CFAr), 149.8
(2CHAr), 143.4, 140.0, 133.9, 130.5, 129.6, 124.4 (2CHAr), 124.3, 122.2,
119.9–119.8 (m, 1CHAr), 119.7, 119.0–118.8 (m,1CHAr), 104.0, 41.0,
25.8, 22.2 (2CH3). Anal. Calcd. For C24H22F2N6O5S: C, 52.94; H, 4.07; N,




3c (222 mg). 4c (159 mg, 95%). 1H NMR (400 MHz, DMSO-d6) δ 9.45
(bs, 4H), 8.57–8.55 (m, 2H), 7.32–7.30 (m, 2H), 7.39 (s, 1H), 7.05–7.01
(m, 1H), 6.91–6.93 (m, 1H), 6.44 (s, 1H), 3.30–3.11 (m, 3H), 1.07 (s,
3H), 1.04–1.01 (m, 6H); 13C NMR (75 MHz, DMSO-d6) δ 159.4, 153.6,
151.9, 151.9–149.5 (m, 2CFAr), 149.9 (2CHAr), 145.2, 141.3, 134.7,
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119.0, 117.9–117.8 (m,1CHAr), 105.1, 44.0, 25.8, 23.3 (2CH3), 21.9.
Anal. Calcd. For C25H24F2N6O5S: C, 53.76; H, 4.33; N, 15.05. Found: C,




3d (226 mg). 4d (168 mg, 98%).1H NMR (300 MHz, DMSO-d6) δ 9.69
(bs, 3H), 8.67 (d, 2H, J=5.5 Hz), 7.41 (d, 2H, J=5.5 Hz), 7.36 (s, 1H),
7.00–6.96 (m, 1H), 6.89–6.87 (m, 1H), 6.50 (s, 1H), 4.99 (bs, 1H), 3.21–
3.09 (m, 3H), 1.86–1.79 (m, 2H), 1.06 (s, 3H), 1.04–1.00 (m, 6H); 13C
NMR (75 MHz, DMSO-d6) δ 163.0, 154.9, 151.1, 151.3–148.8 (m,
2CFAr), 149.9 (2 CHAr), 144.1, 141.0, 134.3, 131.2, 129.4, 124.0 (2CHAr),
123.8, 122.2, 120.0–119.9 (m, 1CHAr), 119.6, 119.2–118.9 (m,1 CHAr),
103.7, 45.8, 27.0, 24.9 (2CH3), 21.4, 17.9. Anal. Calcd. For





3e (226 mg). 4e (145 mg, 84%). 1H NMR (400 MHz, DMSO-d6) δ 9.82
(bs, 4H), 8.59 (d, 2H, J=5.4 Hz), 7.35 (d, 2H, J=5.4 Hz), 7.16–7.12 (m,
1H), 7.12 (s, 1H), 7.11–7.10 (m, 1H), 6.38 (s, 1H), 3.78 (s, 6H), 3.081–
2.96 (m, 1H), 1.09 (s, 3H), 1.07 (s, 3H); 13C NMR (100 MHz, DMSO-d6)
δ 160.9, 153.8, 152.5, 152.0–149.4 (m, 2CFAr), 149.9 (2CHAr), 142.0,
138.8, 130.2, 130.1, 129.9, 124.3, 124.1 (2CHAr), 120.0, 119.9 (m,
1CHAr), 119.5, 119.0 (m, 1CHAr), 105.1, 49.7 (2CH3), 23.9, 21.4 (2CH3).
Anal. Calcd. For C25H25F2N7O5S: C, 52.35; H, 4.39; N, 17.09. Found: C,




3f (234 mg). 4f (153 mg, 85%). 1H NMR (300 MHz, DMSO-d6) δ
9.01–8.99 (bs, 3H), 8.68 (d, 2H, J=5.5 Hz), 7.85 (d, 2H, J=5.5 Hz),
7.27–7.10 (m, 3H), 6.45 (s, 1H), 6.00 (bs, 1H), 3.75–3.59 (m, 4H),
3.081–2.96 (m, 1H), 1.78–1.69 (m, 4H), 1.11 (s, 3H), 1.08 (s, 3H); 13C
NMR (75 MHz, DMSO-d6) δ 162.3, 154.9, 153.6, 151.8–149.7 (m,
2CFAr), 150.2 (2CHAr), 142.5, 138.4, 131.3, 130.6, 129.2, 124.4 (2CHAr),
124.3, 120.2, 120.0 (m, 1CHAr), 119.1, 119.0 (m, 1CHAr), 103.7, 50.1
(2CH2), 25.0, 24.8 (2CH2), 21.4 (2CH3). Anal. Calcd. For C27H27F2N7O5S:
C, 54.08; H, 4.54; N, 16.35. Found: C, 54.33; H, 4.76; N, 16.08.
Biological Assays
Hsp90 Assays
The Hsp90 assay is based on the competition of fluorescently
labelled geldanamycin (FITC-GM) for the binding to Hsp90.[61]
Because FITC-GM binds to the ATP binding pocket of Hsp90, the
assay is able to detect ATP-competitive inhibitors. Hsp90 assays
were performed at Reaction Biology Corporation using human
recombinant Hsp90α at a 30 nm concentration (GenBank Accession
No. NM_005348) with His-tag, MW=90 kDa, expressed in E.coli
expression system. The reaction buffer consisted in 20 mM HEPES,
pH 7.5, 50 mM NaCl, 10 mM MgCl2, 0.02% Brij 35, Add fresh: 2 mM
DTT, 0.02 mg/ml BSA, 1% DMSO. The compounds were firstly
solubilized at 10 mM in 100% DMSO, then serially diluted 1 to 3 (10
concentrations) starting from 100 μM. Geldanamycin was used as a
positive control. Compounds were delivered into the enzyme
mixture by Acoustic technology (Echo550; nanoliter range), and
incubated for 30 min. The FITC-labeled Geldanamycin probe was
added at a 5 nm concentration to initiate the reaction and
incubated for 3 hr at room temperature with gentle mixing.
Fluorescence polarization was then read and IC50 values and curve
fits were calculated using Prism (GraphPad Software).
Kinase Assays
Kinase assays (B-RafWT, B-RafV600E and PDHK1) were performed at
Reaction Biology Corporation using the “HotSpot” assay platform.[62]
To this aim, specific kinase/substrate pairs along with required
cofactors were prepared in reaction buffer; 20 mm Hepes pH 7.5,
10 mm MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM
Na3VO4, 2 mm DTT, 1% DMSO. The compounds were first
solubilized at 10 mm in 100% DMSO, then serially diluted 1 to 3 (10
concentrations) starting from 100 μM. GW5074 was used as a
positive control. Compounds were delivered into the reaction,
followed ~20 min later by addition of a mixture of ATP (Sigma) and
33P-ATP (PerkinElmer) to a final 10 μm concentration to initiate the
reaction. Reactions were carried out at 25 °C for 120 min, followed
by spotting of the reactions onto P81 ion exchange filter paper
(Whatman). Unbound phosphate was removed by extensive
washing of filters in 0.75% phosphoric acid. After subtraction of
background derived from control reactions containing inactive
enzyme, kinase activity data were expressed as the percent
remaining kinase activity in test samples compared to vehicle
(dimethyl sulfoxide) reactions. IC50 values and curve fits were
obtained using Prism (GraphPad Software).
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